Literature DB >> 27228567

Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26.

David Kung-Chun Chiu1, Iris Ming-Jing Xu1, Robin Kit-Ho Lai1, Aki Pui-Wah Tse1, Larry Lai Wei1, Hui-Yu Koh1, Lynna Lan Li1, Derek Lee1, Regina Cheuk-Lam Lo1,2, Chun-Ming Wong1,2, Irene Oi-Lin Ng1,2, Carmen Chak-Lui Wong1,2.   

Abstract

UNLABELLED: A population of stromal cells, myeloid-derived suppressor cells (MDSCs), is present in tumors. Though studies have gradually revealed the protumorigenic functions of MDSCs, the molecular mechanisms guiding MDSC recruitment remain largely elusive. Hypoxia, O2 deprivation, is an important factor in the tumor microenvironment of solid cancers, whose growth often exceeds the growth of functional blood vessels. Here, using hepatocellular carcinoma as the cancer model, we show that hypoxia is an important driver of MDSC recruitment. We observed that MDSCs preferentially infiltrate into hypoxic regions in human hepatocellular carcinoma tissues and that hypoxia-induced MDSC infiltration is dependent on hypoxia-inducible factors. We further found that hypoxia-inducible factors activate the transcription of chemokine (C-C motif) ligand 26 in cancer cells to recruit chemokine (C-X3-C motif) receptor 1-expressing MDSCs to the primary tumor. Knockdown of chemokine (C-C motif) ligand 26 in cancer cells profoundly reduces MDSC recruitment, angiogenesis, and tumor growth. Therapeutically, blockade of chemokine (C-C motif) ligand 26 production in cancer cells by the hypoxia-inducible factor inhibitor digoxin or blockade of chemokine (C-X3-C motif) receptor 1 in MDSCs by chemokine (C-X3-C motif) receptor 1 neutralizing antibody could substantially suppress MDSC recruitment and tumor growth.
CONCLUSION: This study unprecedentedly reveals a novel molecular mechanism by which cancer cells direct MDSC homing to primary tumor and suggests that targeting MDSC recruitment represents an attractive therapeutic approach against solid cancers. (Hepatology 2016;64:797-813).
© 2016 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27228567     DOI: 10.1002/hep.28655

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  74 in total

1.  Hypoxia induces universal but differential drug resistance and impairs anticancer mechanisms of 5-fluorouracil in hepatoma cells.

Authors:  Jing-Qiu Li; Xian Wu; Lu Gan; Xiang-Liang Yang; Ze-Hong Miao
Journal:  Acta Pharmacol Sin       Date:  2017-07-10       Impact factor: 6.150

2.  An Overview of Advances in Cell-Based Cancer Immunotherapies Based on the Multiple Immune-Cancer Cell Interactions.

Authors:  Jialing Zhang; Stephan S Späth; Sherman M Weissman; Samuel G Katz
Journal:  Methods Mol Biol       Date:  2020

3.  Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy.

Authors:  Keehoon Jung; Takahiro Heishi; Omar F Khan; Piotr S Kowalski; Joao Incio; Nuh N Rahbari; Euiheon Chung; Jeffrey W Clark; Christopher G Willett; Andrew D Luster; Seok Hyun Yun; Robert Langer; Daniel G Anderson; Timothy P Padera; Rakesh K Jain; Dai Fukumura
Journal:  J Clin Invest       Date:  2017-07-10       Impact factor: 14.808

Review 4.  Can Exercise-Induced Modulation of the Tumor Physiologic Microenvironment Improve Antitumor Immunity?

Authors:  Xiaojie Zhang; Kathleen A Ashcraft; Allison Betof Warner; Smita K Nair; Mark W Dewhirst
Journal:  Cancer Res       Date:  2019-05-08       Impact factor: 12.701

5.  Endoplasmic reticulum stress induced LOX-1 CD15+ polymorphonuclear myeloid-derived suppressor cells in hepatocellular carcinoma.

Authors:  Jiang Nan; Yan-Fang Xing; Bo Hu; Jian-Xin Tang; Hui-Min Dong; Yu-Mei He; Dan-Yun Ruan; Qing-Jian Ye; Jia-Rong Cai; Xiao-Kun Ma; Jie Chen; Xiu-Rong Cai; Ze-Xiao Lin; Xiang-Yuan Wu; Xing Li
Journal:  Immunology       Date:  2017-12-21       Impact factor: 7.397

Review 6.  Hypoxia-inducible factors and innate immunity in liver cancer.

Authors:  Vincent Wai-Hin Yuen; Carmen Chak-Lui Wong
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

Review 7.  Tumor Hypoxia As an Enhancer of Inflammation-Mediated Metastasis: Emerging Therapeutic Strategies.

Authors:  Josh W DiGiacomo; Daniele M Gilkes
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

Review 8.  The Role of Myeloid-Derived Suppressor Cells in Viral Infection.

Authors:  Megan A O'Connor; Jessica L Rastad; William R Green
Journal:  Viral Immunol       Date:  2017-01-04       Impact factor: 2.257

Review 9.  Chemokines and the immune response to cancer.

Authors:  Aleksandra J Ozga; Melvyn T Chow; Andrew D Luster
Journal:  Immunity       Date:  2021-04-10       Impact factor: 31.745

Review 10.  Therapeutic targeting of the hypoxic tumour microenvironment.

Authors:  Dean C Singleton; Andrew Macann; William R Wilson
Journal:  Nat Rev Clin Oncol       Date:  2021-07-29       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.